199 related articles for article (PubMed ID: 25381564)
21. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
22. Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.
Wen Z; Huang Y; Ling Z; Chen J; Wei X; Su R; Tang Z; Wen Z; Deng Y; Hu Z
Dis Markers; 2020; 2020():4716793. PubMed ID: 33488842
[TBL] [Abstract][Full Text] [Related]
23. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
[TBL] [Abstract][Full Text] [Related]
24. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
25. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.
Wang YF; Feng FL; Zhao XH; Ye ZX; Zeng HP; Li Z; Jiang XQ; Peng ZH
World J Gastroenterol; 2014 Apr; 20(14):4085-92. PubMed ID: 24744600
[TBL] [Abstract][Full Text] [Related]
26. Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma.
Chen Z; Wang Y; Fang M
Cancer Med; 2020 Feb; 9(4):1392-1399. PubMed ID: 31881123
[TBL] [Abstract][Full Text] [Related]
27. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
28. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
29. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
30. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.
Gui JC; Yan WL; Liu XD
Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571
[TBL] [Abstract][Full Text] [Related]
31. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer.
Luo H; Shen K; Li B; Li R; Wang Z; Xie Z
Oncol Lett; 2020 Jul; 20(1):742-750. PubMed ID: 32566000
[TBL] [Abstract][Full Text] [Related]
33. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Bravi S; Ardemagni A; Zerbi A
Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
35. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
[TBL] [Abstract][Full Text] [Related]
36. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
[TBL] [Abstract][Full Text] [Related]
37. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
38. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
39. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
[TBL] [Abstract][Full Text] [Related]
40. Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease.
Natsios A; Vezakis A; Kaparos G; Fragulidis G; Karakostas N; Kouskouni E; Logothetis E; Polydorou A
J BUON; 2015; 20(4):1030-6. PubMed ID: 26416052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
